triiodothyronine has been researched along with Bone Loss, Perimenopausal in 11 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study was to evaluate the effects of treatment with alendronate in patients affected by hyperthyroidism and osteoporosis." | 7.69 | Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. ( Affinito, P; Arlotta, F; Cascone, E; Di Carlo, C; Lupoli, G; Nappi, C; Nuzzo, V; Vitale, G; Vollery, M, 1996) |
| " The aim of the present study was to evaluate the effects of treatment with alendronate in patients affected by hyperthyroidism and osteoporosis." | 3.69 | Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. ( Affinito, P; Arlotta, F; Cascone, E; Di Carlo, C; Lupoli, G; Nappi, C; Nuzzo, V; Vitale, G; Vollery, M, 1996) |
| "Insulin-like growth factor binding proteins (IGFBPs) modulate the actions and bioavailability of insulin-like growth factors (IGFs), however, their regulation in vivo is incompletely understood." | 2.69 | Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women. ( Blum, WF; Brixen, K; Flyvbjerg, A; Kassem, M; Mosekilde, L, 1998) |
| "We conclude that treatment of postmenopausal osteoporosis with oestrogen/progestogen for 3 years results in net spinal bone gain and a positive effect on calcium balance slightly better than that of intermittent etidronate." | 2.67 | A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis. ( Charles, P; Hasling, C; Jensen, FT; Mosekilde, L, 1994) |
| "To elucidate the role of PTH in postmenopausal bone loss, we studied 33 postmenopausal patients who received total thyroidectomy due to thyroid carcinoma." | 1.29 | Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism. ( Fujiyama, K; Ito, M; Kiriyama, T; Nagataki, S; Nakata, K; Yamashita, S; Yokoyama, N, 1995) |
| "To determine the effect of long-term use of thyroid hormone on bone mineral density (BMD) in elderly women and the potential mitigating effects of estrogen replacement therapy." | 1.29 | Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. ( Barrett-Connor, EL; Morton, DJ; Schneider, DL, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (72.73) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murphy, E | 1 |
| Glüer, CC | 1 |
| Reid, DM | 1 |
| Felsenberg, D | 1 |
| Roux, C | 1 |
| Eastell, R | 1 |
| Williams, GR | 1 |
| Karga, H | 1 |
| Giagourta, I | 1 |
| Papaioannou, G | 1 |
| Katsichti, P | 1 |
| Pardalakis, A | 1 |
| Kassi, G | 1 |
| Zagoreou, A | 1 |
| Triantaphyllopoulou, M | 1 |
| Zerva, C | 1 |
| Fujiyama, K | 1 |
| Kiriyama, T | 1 |
| Ito, M | 1 |
| Nakata, K | 1 |
| Yamashita, S | 1 |
| Yokoyama, N | 1 |
| Nagataki, S | 1 |
| Schneider, DL | 1 |
| Barrett-Connor, EL | 1 |
| Morton, DJ | 1 |
| Hasling, C | 2 |
| Charles, P | 3 |
| Jensen, FT | 1 |
| Mosekilde, L | 4 |
| Lupoli, G | 1 |
| Nuzzo, V | 1 |
| Di Carlo, C | 1 |
| Affinito, P | 1 |
| Vollery, M | 1 |
| Vitale, G | 1 |
| Cascone, E | 1 |
| Arlotta, F | 1 |
| Nappi, C | 1 |
| Langdahl, BL | 1 |
| Loft, AG | 1 |
| Møller, N | 1 |
| Weeke, J | 1 |
| Eriksen, EF | 2 |
| Kassem, M | 1 |
| Brixen, K | 1 |
| Blum, WF | 1 |
| Flyvbjerg, A | 1 |
| Duntas, LH | 1 |
| Mantzou, E | 1 |
| Koutras, DA | 1 |
| Steiniche, T | 1 |
| Melsen, F | 1 |
| Schoutens, A | 1 |
| Laurent, E | 1 |
| Markowicz, E | 1 |
| Lisart, J | 1 |
| De Maertelaer, V | 1 |
5 trials available for triiodothyronine and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Transient changes in thyroid functions tests after zoledronic acid infusion.
Topics: Bone Density Conservation Agents; C-Reactive Protein; Diphosphonates; Female; Humans; Hydrocortisone | 2011 |
A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.
Topics: Administration, Oral; Aged; Bone Density; Calcium; Drug Administration Schedule; Drug Therapy, Combi | 1994 |
Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women.
Topics: Aged; Calcitriol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedul | 1998 |
Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status.
Topics: Aged; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Middle A | 2001 |
The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime.
Topics: Aged; Bone Density; Bone Remodeling; Drug Administration Schedule; Drug Therapy, Combination; Etidro | 1991 |
6 other studies available for triiodothyronine and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Analysis of Variance; Bone Density; Female; Fractur | 2010 |
Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism.
Topics: Adult; Aged; Bone Density; Calcifediol; Calcitriol; Calcium; Female; Humans; Hypoparathyroidism; Inc | 1995 |
Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Cross-Sectional Studies; Drug Combina | 1994 |
Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole.
Topics: Adult; Alendronate; Bone Density; Female; Humans; Hyperthyroidism; Methimazole; Middle Aged; Osteoca | 1996 |
Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Alkaline Phosphatase; Amino Acids; Bone Density; | 1997 |
Serum triiodothyronine, bone turnover, and bone mass changes in euthyroid pre- and postmenopausal women.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Density; Estradiol; Estrogens; Female; Humans; Hyd | 1991 |